NCT03277352View on ClinicalTrials.gov

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 21, 2017

Primary Completion Date

July 1, 2020

Study Completion Date

July 1, 2020

Conditions
Advanced MalignanciesMetastatic Cancer
Interventions
DRUG

INCAGN01876

In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose and schedule according to cohort and treatment group enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.

DRUG

Epacadostat

Epacadostat will be self-administered orally at the protocol-defined dose.

DRUG

Pembrolizumab

Pembrolizumab will be administered IV at the protocol-defined dose.

Trial Locations (2)

90025

The Angeles Clinic and Research Institute, Los Angeles

07601

Hackensack University Medical Center, Hackensack

Sponsors
All Listed Sponsors
lead

Incyte Biosciences International Sàrl

INDUSTRY

NCT03277352 - INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | Biotech Hunter | Biotech Hunter